Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With ALS

First Published on Clinicaltrials.gov: 7/27/2005
Status: This study has been completed
ClinicalTrials.gov ID: NCT00125203
Sponsor: The University of Texas Health Science Center at San Antonio
Purpose: The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling.
Phase: II/III
Treatment Type: Injection
Trial Type: Double Blind, Placebo Controlled
Estimated Enrollment: 20
Eligibility: 21 to 85 years. Both genders. No healthy volunteers.
Details: The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.
Collaborator(s):
Location(s):
  • Kansas City, KS, 66160, United States
  • Charlotte, NC, 28203, United States
Primary Investigator: Carlayne E Jackson, MD and Charles B Simpson, MD- University of Texas Health Science Center at San Antonio
Contact:
Trial Protocol as Published on Clinicaltrials.gov:
ClinicalTrials.gov
ALS Forum: